Toggle navigation Welcome Recruiting Now GSK CMV Study Merck V110-911 For our Volunteers Join our Registry Like to know more? Current Studies Previous Studies Meet the Team For Sponsors Contact/Find Us Current StudiesLast updated March 23, 2021 Studies currently being conducted by the SIVS Clinical Trials Program. For more information click on links to go to ClinicalTrials.gov, or contact (409) 772 5278/sivsctp@utmb.edu. Recruiting Current Studies - Recruiting NCT04708041: Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) Recruiting Now! Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Richard Rupp, MD For more information click here NCT04642079: Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age Recruiting Now! For more information, please visit www.nexxstep14study.com or contact Robert Cox, RN 409-772-5278 sivsctp@utmb.edu Sponsor: Pfizer Inc. Principal Investigator: Richard Rupp, MD For clinicaltrials.gov information, click here NCT04525599: A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator Recruiting Now! For more information, please visit www.VaccineStudyForKids.com or contact Robert Cox, RN 409-772-5278 or sivsctp@utmb.edu Sponsor: Astellas Pharma Global Development Inc. (APGD) Principal Investigator: Richard Rupp, MD For clinicaltrials.gov information, click here NCT04144348: Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure Recruiting Soon! Sponsor: ModernaTX, Inc. Principal Investigator: Richard Rupp, MD For more information click here A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults Recruiting Now! Sponsor: Pfizer Inc. Principal Investigator: Richard Rupp, MD For more information click here Active, Not Recruiting Current Studies - Active, Not Recruiting NCT04470427: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 Sponsor: ModernaTX, Inc. Principal Investigator: Richard Rupp, MD For more information click here NCT04368728: Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Sponsor: Pfizer Inc. Principal Investigator: Richard Rupp, MD For more information click here NCT04199689: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Richard Rupp, MD For more information click here NCT03893448: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PNEU-PED) Sponsor: Merck Sharp & Dohme Corp. Principal Investigator (Galveston): Richard Rupp, MD Principal Investigator (Bay Colony): Marcela Navarro, MD For more information click here NCT03738241: A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered IM With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Principal Investigator: Richard Rupp, MD For more information click here NCT03692871: A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Marcela Navarro, MD For more information click here NCT03682120: A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Principal Investigator: Richard Rupp, MD For more information click here NCT03620162: A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Richard Rupp, MD For more information click here NCT03537508: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US Sponsor: Sanofi Pasteur Principal Investigator: Richard Rupp, MD For more information click here NCT03524118: A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Richard Rupp, MD For more information click here NCT03512288: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants (B747-1003) Sponsor: Pfizer Inc. Principal Investigator: Richard Rupp, MD For more information click here NCT03486834: Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002) Sponsor: Merck Sharp & Dohme Corp Principal Investigator: Richard Rupp, MD For more information click here NCT03480763: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) Sponsor: Merck Sharp & Dohme Corp. Principal Investigator: Richard Rupp, MD For more information click here NCT03090191: A phase III, placebo-controlled, randomized, observer-blinded, study to evaluate efficacy, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older (CLOVER) Sponsor: Pfizer Inc. Principal Investigator: Richard Rupp, MD For more information click here
